Cargando…

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

INTRODUCTION: Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth factor receptor mutation (EGFRm). This is an observational study investigating epidemiology, clinical features and tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frega, Stefano, Lorenzi, Martina, Fassan, Matteo, Indraccolo, Stefano, Calabrese, Fiorella, Favaretto, Adolfo, Bonanno, Laura, Polo, Valentina, Zago, Giulia, Lunardi, Francesca, Attili, Ilaria, Pavan, Alberto, Rugge, Massimo, Guarneri, Valentina, Conte, PierFranco, Pasello, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464815/ https://www.ncbi.nlm.nih.gov/pubmed/28427238 http://dx.doi.org/10.18632/oncotarget.15945

Ejemplares similares

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization
por: Polo, Valentina, et al.
Publicado: (2016)

Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature
por: Polo, Valentina, et al.
Publicado: (2015)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
por: Pavan, Alberto, et al.
Publicado: (2021)

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment
por: Frega, Stefano, et al.
Publicado: (2020)

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020)

Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome
por: Pavan, Alberto, et al.
Publicado: (2022)

LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
por: Bonanno, Laura, et al.
Publicado: (2019)

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
por: Boscolo, Alice, et al.
Publicado: (2020)

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Zulato, Elisabetta, et al.
Publicado: (2022)

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
por: Bonanno, Laura, et al.
Publicado: (2022)

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
por: Lorenzi, Martina, et al.
Publicado: (2021)

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment
por: Bonanno, Laura, et al.
Publicado: (2016)

Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
por: Ferro, Alessandra, et al.
Publicado: (2021)

The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments
por: Ferro, Alessandra, et al.
Publicado: (2022)

Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
por: Boldrin, Elisa, et al.
Publicado: (2019)

Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
por: Frega, Stefano, et al.
Publicado: (2020)

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
por: Pavan, A., et al.
Publicado: (2019)

MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data
por: Pasello, Giulia, et al.
Publicado: (2015)

How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center
por: Pasello, Giulia, et al.
Publicado: (2021)

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
por: Pretelli, Giulia, et al.
Publicado: (2023)

A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients
por: Cortiula, Francesco, et al.
Publicado: (2020)

Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review
por: Mantiero, Mara, et al.
Publicado: (2018)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients
por: Zulato, Elisabetta, et al.
Publicado: (2021)

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
por: Urso, Loredana, et al.
Publicado: (2021)

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report
por: Scattolin, Daniela, et al.
Publicado: (2023)

EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience
por: Dal Maso, Alessandro, et al.
Publicado: (2022)

Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy
por: Fortarezza, Francesco, et al.
Publicado: (2021)

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
por: Calabrese, Fiorella, et al.
Publicado: (2022)

Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model
por: Buja, Alessandra, et al.
Publicado: (2020)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2020)

Precision Surgery in NSCLC
por: Cannone, Giorgio, et al.
Publicado: (2023)

The Rarest of Rare Thymic Lesions: A 10-Year Surgical Pathology Experience
por: Calabrese, Fiorella, et al.
Publicado: (2021)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy
por: Bellini, Alice, et al.
Publicado: (2021)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer
por: Perilli, Lisa, et al.
Publicado: (2019)

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
por: Spagnolo, Calogera Claudia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p2dog55rkd9hhmpgrgjukamlth